154 related articles for article (PubMed ID: 7694266)
1. Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP.
Langeler EG; van Uffelen CJ; Blankenstein MA; van Steenbrugge GJ; Mulder E
Prostate; 1993; 23(3):213-23. PubMed ID: 7694266
[TBL] [Abstract][Full Text] [Related]
2. Androgen-dependent growth regulation of and release of specific protein(s) by the androgen receptor containing human prostate tumor cell line LNCaP.
Berns EM; de Boer W; Mulder E
Prostate; 1986; 9(3):247-59. PubMed ID: 2946029
[TBL] [Abstract][Full Text] [Related]
3. LNCaP prostatic adenocarcinoma cells derived from low and high passage numbers display divergent responses not only to androgens but also to retinoids.
Esquenet M; Swinnen JV; Heyns W; Verhoeven G
J Steroid Biochem Mol Biol; 1997 Aug; 62(5-6):391-9. PubMed ID: 9449242
[TBL] [Abstract][Full Text] [Related]
4. Regulation of growth and prostatic marker expression by activin A in an androgen-sensitive prostate cancer cell line LNCAP.
Zhang Z; Zhao Y; Batres Y; Lin MF; Ying SY
Biochem Biophys Res Commun; 1997 May; 234(2):362-5. PubMed ID: 9177276
[TBL] [Abstract][Full Text] [Related]
5. The human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of androgen sensitivity.
van Steenbrugge GJ; van Uffelen CJ; Bolt J; Schröder FH
J Steroid Biochem Mol Biol; 1991; 40(1-3):207-14. PubMed ID: 1958522
[TBL] [Abstract][Full Text] [Related]
6. Steroids inversely affect the biosynthesis and secretion of human prostatic acid phosphatase and prostate-specific antigen in the LNCaP cell line.
Henttu P; Vihko P
J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):349-60. PubMed ID: 1373297
[TBL] [Abstract][Full Text] [Related]
7. Androgens inhibit the proliferation of a variant of the human prostate cancer cell line LNCaP.
Joly-Pharaboz MO; Soave MC; Nicolas B; Mebarki F; Renaud M; Foury O; Morel Y; Andre JG
J Steroid Biochem Mol Biol; 1995 Oct; 55(1):67-76. PubMed ID: 7577722
[TBL] [Abstract][Full Text] [Related]
8. Effect of retinoic acid on the proliferation and secretory activity of androgen-responsive prostatic carcinoma cells.
Fong CJ; Sutkowski DM; Braun EJ; Bauer KD; Sherwood ER; Lee C; Kozlowski JM
J Urol; 1993 May; 149(5):1190-4. PubMed ID: 7683344
[TBL] [Abstract][Full Text] [Related]
9. Variants of the human prostate LNCaP cell line as tools to study discrete components of the androgen-mediated proliferative response.
Soto AM; Lin TM; Sakabe K; Olea N; Damassa DA; Sonnenschein C
Oncol Res; 1995; 7(10-11):545-58. PubMed ID: 8866667
[TBL] [Abstract][Full Text] [Related]
10. Inverse relationships between cell proliferation and basal or androgen-stimulated apolipoprotein D secretion in LNCaP human prostate cancer cells.
Sugimoto K; Simard J; Haagensen DE; Labrie F
J Steroid Biochem Mol Biol; 1994 Nov; 51(3-4):167-74. PubMed ID: 7526888
[TBL] [Abstract][Full Text] [Related]
11. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation.
Kokontis J; Takakura K; Hay N; Liao S
Cancer Res; 1994 Mar; 54(6):1566-73. PubMed ID: 7511045
[TBL] [Abstract][Full Text] [Related]
12. Triiodothyronine modulates growth, secretory function and androgen receptor concentration in the prostatic carcinoma cell line LNCaP.
Esquenet M; Swinnen JV; Heyns W; Verhoeven G
Mol Cell Endocrinol; 1995 Mar; 109(1):105-11. PubMed ID: 7540569
[TBL] [Abstract][Full Text] [Related]
13. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone.
Lee C; Sutkowski DM; Sensibar JA; Zelner D; Kim I; Amsel I; Shaw N; Prins GS; Kozlowski JM
Endocrinology; 1995 Feb; 136(2):796-803. PubMed ID: 7530653
[TBL] [Abstract][Full Text] [Related]
14. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
Zhao XY; Ly LH; Peehl DM; Feldman D
Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780
[TBL] [Abstract][Full Text] [Related]
15. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
[TBL] [Abstract][Full Text] [Related]
16. Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines.
Lin MF; Meng TC; Rao PS; Chang C; Schonthal AH; Lin FF
J Biol Chem; 1998 Mar; 273(10):5939-47. PubMed ID: 9488733
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype.
Hobisch A; Ramoner R; Fuchs D; Godoy-Tundidor S; Bartsch G; Klocker H; Culig Z
Clin Cancer Res; 2001 Sep; 7(9):2941-8. PubMed ID: 11555613
[TBL] [Abstract][Full Text] [Related]
18. The human prostatic carcinoma cell line LNCaP and its derivatives. An overview.
van Steenbrugge GJ; Groen M; van Dongen JW; Bolt J; van der Korput H; Trapman J; Hasenson M; Horoszewicz J
Urol Res; 1989; 17(2):71-7. PubMed ID: 2660395
[TBL] [Abstract][Full Text] [Related]
19. ErbB-2 signaling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCaP C-81 cells.
Lee MS; Igawa T; Yuan TC; Zhang XQ; Lin FF; Lin MF
Oncogene; 2003 Feb; 22(5):781-96. PubMed ID: 12569372
[TBL] [Abstract][Full Text] [Related]
20. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
